Any news for July for LLY

Here is some news about LLY for July: 1. **Eli Lilly's Taltz Fails to Meet Primary Endpoint in Phase 3 Trial**: Eli Lilly announced on July 5, 2024, that its drug Taltz did not meet the primary endpoint in a Phase 3 trial for the treatment of diabetic macular edema (DME). This news could have implications for the company's DME treatment strategy and investor sentiment. 2. **Eli Lilly's M&A Moves in July**: Eli Lilly has been active in the mergers and acquisitions space in July, with two notable deals. On July 10, 2024, the company announced the acquisition of AnPac Bio-Medical Science's cancer diagnostic assets, and on July 24, 2024, Eli Lilly entered into an agreement to acquire Immunogen for $8.1 billion. These moves reflect the company's strategy to bolster its pharmaceutical portfolio and potentially impact its stock price. |Ticker|Name|Interval Percentage Change|Date|code|market_code| |---|---|---|---|---|---| |LLY.N|Eli Lilly|-2.139981485069646|20230630-20230731|LLY|169|